MarketResearchReports.Biz has announced addition of new report "EpiCast Report: Gaucher Disease - Epidemiology Forecast To 2024" to its database.
Gaucher Disease (GD) is a rare, inherited lysosomal storage disorder (LSD) that is classified into three forms - Types 1, 2, and 3 - which are distinguished by their symptoms, severity, and neurological involvement. GD affects the ability of cells to break down a specific type of fat, glucocerebroside (GC), as a result of the deficiency or limited activity of the enzyme glucocerebrosidase (GCase). This leads to the harmful accumulation of GC, which is also known as glucosylceramide, in the lysosomes, most commonly in the macrophages and monocytes, throughout the body. The most significant difference between the three types of GD is whether or not there is neurological involvement.
View Full Report at http://www.marketresearchreports.biz/analysis/487693
GlobalData epidemiologists forecast that the total prevalent cases of Type 1 GD in the 7MM will increase from 12,036 cases in 2014 to 13,006 cases in 2024, with the majority of cases occurring in the US and Israel. Types 2 and 3 GD are even more rare than Type 1, with only 121 cases of Type 2 and 613 cases of Type 3 across the 7MM in 2014. GlobalData epidemiologists predict that the total prevalent cases of Type 2 GD in the 7MM will increase from 121 cases in 2014 to 125 cases in 2024, and that the total prevalent cases of Type 3 GD in the 7MM will increase from 613 cases in 2014 to 640 cases in 2024. The disease affects men and women in equal numbers across the 7MM.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/487693
GlobalData epidemiologists used the available data on GD to the best extent possible to provide the most insightful epidemiological forecast for the total prevalent cases and type-specific cases of the disease in the 7MM. GlobalData epidemiologists conducted an exhaustive literature review, and used the most appropriate prevalence estimates. For Israel, where there is a high concentration of Ashkenazi Jews, GlobalData epidemiologists segmented the population into the general population and the Ashkenazi Jewish population, and used population-specific prevalence estimates for the forecast. This provides a more accurate estimate of the prevalence of GD in Israel, considering the higher disease prevalence among the Ashkenazi Jews as compared with the general population. For this forecast, GlobalData epidemiologists used a total GD prevalence estimate, which provides a truer picture of the disease burden within the 7MM.